Grosse Pointe, Michigan, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, is delighted to announce the 1954 Jaguar D-Type Works Competition Car, chassis no. XKD 403, set to feature at its 2025 Amelia Auction, the official auction of The Amelia (Concours d’Elegance). Famously known as ‘OKV 2,’ its Works number plate, the D-Type on offer is among the most important sports racing cars of all time and importantly will be offered without reserve at the March auction. Not on ...

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT).KJ-C2320 is developed based on CARsgen's THANK-uCAR® platform. An investigator-initiated trial is ongoing in China to evaluate KJ-C232 ...

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial (IIT).KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and ...

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-ST-01(NCT04581473). This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Cla ...

Avis Budget Group, Inc. (CAR) is benefiting from strong car rental demand, strategic fleet management, technology investments, and share buybacks, boosting profitability and investor confidence. The Zacks Consensus Estimate for the company’s 2025 earnings is 1.38 per share, indicating an 182% year-over-year increase.The car rental industry, particularly in North America, has been experiencing strong demand driven by changes in consumer behavior, including an emphasis on short-term vehicle access rather than ...

Autolus Therapeutics plc (NASDAQ: AUTL ) is a promising CAR T-cell biotech that recently received FDA approval for AUCATZYL. This is AUTL's main value driver, and it's indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia [ALL]. Based onMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate ...

– Mercedes-Benz's elegant midsize luxury car has outdone its competitors to secure MotorTrend's Golden Calipers for the second time in five years –LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- MotorTrend Group, a Warner Bros. Discovery company, announced today the Mercedes-Benz E-Class as its 2025 Car of the Year award winner. The new E-Class, available as both a sedan and wagon-crossover, claimed the top spot amongst competitors for its elegant, refreshed design, excellent performance, and technology. MOT ...

Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.Data were presented at the American College of Rheumatology 2024.Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee IssueCC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell therapy that expresses ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being cond ...

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells and Plasmablas ...